Regulus Therapeutics Inc (RGLS)
2.50
+0.20
(+8.70%)
USD |
NASDAQ |
May 01, 16:00
2.51
+0.01
(+0.40%)
After-Hours: 20:00
Regulus Therapeutics Cash from Financing (Quarterly): -0.873M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.873M |
| September 30, 2023 | 0.287M |
| June 30, 2023 | 13.21M |
| March 31, 2023 | -0.805M |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 4.489M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.002M |
| December 31, 2021 | 32.41M |
| September 30, 2021 | -0.004M |
| June 30, 2021 | 15.00M |
| March 31, 2021 | 6.336M |
| December 31, 2020 | 10.06M |
| September 30, 2020 | -1.068M |
| June 30, 2020 | 0.593M |
| March 31, 2020 | -0.067M |
| December 31, 2019 | 24.51M |
| September 30, 2019 | -0.064M |
| June 30, 2019 | 14.83M |
| March 31, 2019 | 0.657M |
| December 31, 2018 | -2.572M |
| September 30, 2018 | -0.884M |
| June 30, 2018 | -0.075M |
| March 31, 2018 | 0.701M |
| Date | Value |
|---|---|
| December 31, 2017 | 0.00 |
| September 30, 2017 | 43.15M |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.268M |
| December 31, 2016 | -0.042M |
| September 30, 2016 | 0.23M |
| June 30, 2016 | 19.84M |
| March 31, 2016 | 0.528M |
| December 31, 2015 | 1.639M |
| September 30, 2015 | 3.541M |
| June 30, 2015 | 0.922M |
| March 31, 2015 | 0.915M |
| December 31, 2014 | 77.87M |
| September 30, 2014 | 0.157M |
| June 30, 2014 | 0.033M |
| March 31, 2014 | 10.18M |
| December 31, 2013 | -0.004M |
| September 30, 2013 | 46.24M |
| June 30, 2013 | 0.06M |
| March 31, 2013 | 0.173M |
| December 31, 2012 | 67.01M |
| September 30, 2012 | 3.761M |
| June 30, 2012 | -0.218M |
| March 31, 2012 | -0.074M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.068M
Minimum
Sep 2020
32.41M
Maximum
Dec 2021
6.254M
Average
0.287M
Median
Sep 2023
Cash from Financing (Quarterly) Benchmarks
| ACADIA Pharmaceuticals Inc | 5.434M |
| ADMA Biologics Inc | -38.99M |
| FibroGen Inc | -0.246M |
| Protara Therapeutics Inc | 0.00 |
| Amylyx Pharmaceuticals Inc | 0.23M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -6.125M |
| Cash from Investing (Quarterly) | 4.932M |
| Free Cash Flow | -27.38M |
| Free Cash Flow Per Share (Quarterly) | -0.3062 |
| Free Cash Flow Yield | -57.90% |